Stockreport

Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome [Ya...

Mirum Pharmaceuticals, Inc. - common stock  (MIRM) 
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
PDF LIVMARLI is the first and only approved medication to treat cholestatic pruritus in patients with Alagille syndrome in Canada FOSTER CITY, Calif., April 02, 2024 BUSI [Read more]